Qualigen Therapeutics Inc (QLGN) Stock
QLGN is no longer traded. Qualigen Therapeutics was delisted from the Nasdaq in January 2026.
Prices on this page are historical; the last trade was January 20, 2026 at $2.33.
Qualigen Therapeutics stock price history
QLGN final trading statistics
- Final close
- $2.33
- Final trading day
- Jan 20, 2026
- Market cap at delisting
- $4.74M
- Shares outstanding
- 2.03M
- Final 52-week range
- $1.61 – $8.81
- Avg. volume (final 3 mo.)
- 1,220,900
- All-time high (split-adj.)
- $76250.01 · Jun 2017
- All-time low (split-adj.)
- $0.10 · Nov 2024
- Return since IPO
- -53.0%
- Beta
- 0.28
- Book value / share
- -$4.12
- Price / book
- -0.56
Qualigen Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$6.2M | -$6.54 |
| FY2023 | $5.20M | -$13.4M | -$9.47 |
| FY2022 | $4.98M | -$21.0M | -$4.10 |
| FY2021 | $5.65M | -$17.9M | -$6.10 |
| FY2020 | $4.31M | -$20.4M | $1.07 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Qualigen Therapeutics stock FAQ
What happened to Qualigen Therapeutics stock?
Qualigen Therapeutics stock was delisted from the Nasdaq. Its final close was $2.33 on January 20, 2026.
Is QLGN stock still trading?
No. QLGN was delisted from the Nasdaq in January 2026 and no longer trades on a U.S. exchange.
What was the last price of QLGN stock?
QLGN closed at $2.33 on its final trading day, January 20, 2026, for a market value of about $4.74M.
What were Qualigen Therapeutics's revenue and earnings in its last full fiscal year?
Qualigen Therapeutics reported revenue of $0.00 and net income of -$6.2M in fiscal 2024, its last full year as a public company.
When did Qualigen Therapeutics go public?
Qualigen Therapeutics Inc stock began trading on June 24, 2015.